Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Engage Grants Program

University of Guelph

$25,000.00

Co-crystallization of hemp oil constituents and assessment for bioaccessibility using the TIM-1 in vitro gastrointestinal digestion model

FY 2017-18

Summary
In Canada, cannabis may be prescribed as a physician-recommended herbal therapy. While cannabis is typicallysmoked, inhalation of burned dry plant matter has obvious inherent health risks. Oral administration offersseveral key advantages, including elimination of pulmonary health risks and more accurate dosing of activeingredients such as THC and CBD. Oral administration does, however, suffer certain shortcomings andchallenges as well. Bioavailability is defined as the proportion of a drug or other substance that enterscirculation when introduced into the body and so is able to have an active effect. This is therefore an importantproperty to assess when developing cannabis formulations for oral administration. Research has thus far shownthat extensive liver metabolism reduces the oral bioavailability of THC to roughly 2-14%, while inhalation ofmarijuana smoke offers a systemic bioavailability generally ranging between 10-35%. Others have reportedTHC bioavailability after oral ingestion to be approximately 6% compared to 25% after smoking. The goal ofour current research project is to develop novel formulations of cannabinoids in an effort to improve oralbioavailability. Assessing for bioavailability poses some serious challenges, as human or animal subjects arerequired and plasma samples must be drawn. The TIM-1 simulated in vitro gastrointestinal digestion modeldeveloped by TNO in the Netherlands is an advanced dissolution model with high correlation to in vivo testingand has been validated for use in drug delivery testing. Novel formulations can be assessed for bioavailabilityin a quick and cost-effective manner without the need for ethical approval when dealing with human or animaltest subjects. This will allow rapid assessments of formulations and significantly increase the rate of innovationand discovery into enhancing oral bioavailability of cannabinoids.
Program
Engage Grants Program
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
518092-2017
Name nom
Rogers, Michael
Department département
Food Science
Organization id
24
Institution établissement
University of Guelph
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2017
Competition year année de concours
2017
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1553
Committee name en
Ontario Internal Decision Committee
Committee name fr
Comité de décision interne pour l'Ontario
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
6101
Research subject group en
Food science and technology
Research subject group fr
Science et technologie de l'alimentation
Research subject en
Food chemistry and analysis
Research subject fr
Chimie alimentaire et analyse
Partie
1
Nb partie
1
Application title
Co-crystallization of hemp oil constituents and assessment for bioaccessibility using the TIM-1 in vitro gastrointestinal digestion model
Keyword
NSERC
Application summary
In Canada, cannabis may be prescribed as a physician-recommended herbal therapy. While cannabis is typicallysmoked, inhalation of burned dry plant matter has obvious inherent health risks. Oral administration offersseveral key advantages, including elimination of pulmonary health risks and more accurate dosing of activeingredients such as THC and CBD. Oral administration does, however, suffer certain shortcomings andchallenges as well. Bioavailability is defined as the proportion of a drug or other substance that enterscirculation when introduced into the body and so is able to have an active effect. This is therefore an importantproperty to assess when developing cannabis formulations for oral administration. Research has thus far shownthat extensive liver metabolism reduces the oral bioavailability of THC to roughly 2-14%, while inhalation ofmarijuana smoke offers a systemic bioavailability generally ranging between 10-35%. Others have reportedTHC bioavailability after oral ingestion to be approximately 6% compared to 25% after smoking. The goal ofour current research project is to develop novel formulations of cannabinoids in an effort to improve oralbioavailability. Assessing for bioavailability poses some serious challenges, as human or animal subjects arerequired and plasma samples must be drawn. The TIM-1 simulated in vitro gastrointestinal digestion modeldeveloped by TNO in the Netherlands is an advanced dissolution model with high correlation to in vivo testingand has been validated for use in drug delivery testing. Novel formulations can be assessed for bioavailabilityin a quick and cost-effective manner without the need for ethical approval when dealing with human or animaltest subjects. This will allow rapid assessments of formulations and significantly increase the rate of innovationand discovery into enhancing oral bioavailability of cannabinoids.